Healthcare entity
regulation is the sole category represented across all 3 tracked stories. Kyle Diamantas is most often covered alongside Robert F. Kennedy Jr., which appears in 3 of these 3 stories. The 53-day window averages about 0.4 stories each week. Their average consequence score of 6.3 runs above the beat's 6 for that window.
Last mentioned: Aug 19, 2026
Entity pulse
Coverage balance Balanced directional read. Positive and negative coverage are within 0 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
regulation is the sole category represented across all 3 tracked stories. Kyle Diamantas is most often covered alongside Robert F. Kennedy Jr., which appears in 3 of these 3 stories. The 53-day window averages about 0.4 stories each week. Their average consequence score of 6.3 runs above the beat's 6 for that window. Each story carries 4 original sources on average, compared with 3.8 for the broader beat in this window. This profile follows 3 Healthcare stories mentioning Kyle Diamantas across the period from June 28, 2026 to August 19, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 453 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Kyle Diamantas. Shared-story counts are live from our verified record — not editorial picks.
A White House health-policy aide with a hand in the childhood vaccine-schedule rewrite is tapped to run the FDA during a multistate cyclospora outbreak. Health systems and public-health officials now weigh the operational impact of leadership churn and a nominee whose recommendations physicians say lack scientific support.
Public health officials are responding to 17 active foodborne illness outbreaks—including Cyclospora and Salmonella—by proposing that food companies must notify the FDA of GRAS ingredients. This shift could give epidemiologists critical data to trace outbreaks faster and prevent contamination in imported produce, where foreign inspection gaps leave the food supply vulnerable.
Source: wbaltv.com · wmtw.com
The FDA is developing a pilot program to accelerate early-stage clinical trials, potentially reducing development timelines by 6 to 12 months, HHS Secretary Kennedy announced. For health systems and patients, this could mean faster access to innovative therapies and a more efficient regulatory pathway.
Kyle Diamantas is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
